December 6, 2016 / by / News
CALGARY, AB – December 6, 2016. SolAeroMed Inc. is excited to report a brand new investment opportunity. Please click here to find out more information about our new investment announcement for shares with a warrant.
Read more
SolAeroMed is actively recruiting non CF bronchiectasis patients in Calgary
January 11, 2022 / by / News
The global pandemic has compromised many clinical trials, including SolAeroMed’s ongoing Phase II Bronchiectasis trial. Recruitment of non CF bronchiectasis patients is gaining lost momentum
Read more
Publication of S1226 clinical results in medRxiv Dec 13 2021.
December 28, 2021 / by / News
SolAeroMed clinicians have published S1226 clinical trial results in CF and non CF Bronchiectasis, where positive safety and efficacy signals are described across all dosing levels and in all patients.
Read more
Presentation at ISAM May 2021, Boise Idaho
June 11, 2021 / by / News
SolAeroMed CEO presented clinical study results in Bronchiectasis at the International Socieity of Aerosol Medicine meeting in Boise Idaho in May 2021. Ensuing discussion led to 3rd party interest from US clinicians to engage in future clinical trials of S1226.
Read more
$1.5 million investment round announced to progress COVID -19 clinical trial
January 15, 2021 / by / News
We have constructed a term sheet to raise $1.5 million to support a Phase II clinical trial in COVID patients in local Alberta hospitals. We maintain the current $7.50 share price and $20M company valuation. Proceeds will be used over the next few months to: Support the purchase of drug components (500 treatment doses) Progress
Read more
Health Canada signs regulatory approval for S-1226 COVID Phase II clinical trial
December 31, 2020 / by / News
On the eve of 2021 SolAeroMed received regulatory notification from Health Canada that our proposed clinical trial of S-1226 in COVID patients received official approval. This is approval was a long time coming and SolAeroMed management had been in discussions with Health Canada for 6 months working to address issues around the design of the
Read more
SolAeroMed advances discussion with European partners on development of S-1229 as platform drug technology based on granting of European cyclodextrin patent.
December 1, 2020 / by / News
While most of SolAeroMed efforts are focused on advancing clinical trial development of our lead CO2/perflubron S-1226 drug, we have also made recent progress in our S-1229 Cyclodextrin drug technology. Our pre-clinical and in vitro R&D demonstrates that inhaled cyclodextrin can remove excess cholesterol and repair dysfunctional lung surfactant. Dysfunctional surfactant is a feature of
Read more
SolAeroMed is promoting a new S1226 Phase II trial in Cystic Fibrosis
June 16, 2019 / by / News
March 15, 2019 A Scientific Poster was presented at a University of Calgary event in Q1 2019
Read more
S1226 Portable Delivery Advanced Design Concept
June 27, 2018 / by / News
We have now completed a $150,000 grant with Calgary based SAIT, which build on the earlier work by Melbourne based Hydrix. The result is a more advanced design for our portable S1226 delivery device.
Read more
Treatment of Acute Asthma in the ICU
June 26, 2018 / by / News
In October 2017 we were able to treat a severely ill asthmatic patient in Calgary ICU with our experimental S1226 drug. Results were in the words of the lead clinician ‘shockingly good’. This case study was presented in May at the American Thoracic Society meeting in San Diego. Full presentation available in poster form.
Read more
SolAeroMed Investment Announcement
December 6, 2016 / by / News
CALGARY, AB – December 6, 2016. SolAeroMed Inc. is excited to report a brand new investment opportunity. Please click here to find out more information about our new investment announcement for shares with a warrant.
Read more